Video summary
GLP-1 drugs are injectable peptides administered weekly via subcutaneous injection that function by mimicking gut hormones to signal the brain and regulate metabolism. These medications work by reducing appetite, slowing gastric emptying, improving insulin sensitivity, and promoting fat loss. The most well-known drug in this class is Ozempic, also known as semaglutide, which contains a single GLP-1 agonist and has helped users lose an average of 15 to 20% of their body weight over six months to a year. Following its success, tirzepatide, marketed under the brand name Mounjaro, was introduced with a dual mechanism that combines a GLP-1 agonist with a GIP agonist to further enhance insulin sensitivity and weight loss results.
Recent advancements have led to the development of retatrutide, a third-generation drug featuring three agonists: GLP-1, GIP, and glucagon. The addition of the glucagon component is particularly significant as it increases energy expenditure by raising the basal metabolic rate, causing the body to burn more calories. This mechanism also aids the liver in dumping fat, thereby improving liver health, while effectively targeting visceral fat. Although these drugs are highly effective for individuals with a BMI significantly over 30 or 40, they come with notable drawbacks that require careful consideration before use.
One of the primary side effects experienced by some users is gastric distress, which can manifest as nausea, diarrhea, or vomiting, leading to a condition often described in medical circles as "forced anorexia." While the speaker personally tolerated the medication well after titrating up from low doses, many others struggle with these symptoms, making it difficult for them to maintain adequate protein and calorie intake. For individuals who are already maintaining a healthy body weight or those relying on these drugs for longevity purposes without significant obesity, this loss of appetite can be a serious disadvantage that requires strict dietary management through high-calorie shakes and supplements.
The most critical concern regarding current GLP-1 medications is their lack of muscle-sparing properties, as users often lose fat and muscle in nearly equal proportions, particularly with semaglutide. While tirzepatide shows slightly better results in preserving muscle mass, published studies on retatrutide are not yet available since it is still in the final stages of FDA approval. However, anecdotal evidence suggests that retatrutide may offer a significant advantage by burning fat more efficiently while better preserving muscle tissue compared to its predecessors. Additionally, it appears to have a less intense anorexic effect than other drugs in the class, potentially allowing users to avoid the extreme lack of appetite that complicates nutrition for some patients.
Read the full video transcript
So, GLP-1s, these are injectable,
typically weekly, subcutaneous
injectable with a little baby like
insulin-type syringe.
And it's a it's a drug that really it's
a peptide. It's it's a signaling
mechanism that signals your brain. It's
it these GLP-1s target gut or mimic gut
hormones to target the receptor signals
in your brain to reduce your appetite,
slow gastric emptying, improve insulin
sensitivity, and promote fat loss. And
there has been a tremendous progression.
The big one that came out years ago
you've all heard of is Ozempic,
otherwise known as semaglutide. That has
one agonist in it. And so it's a GLP-1.
That's all it is. And it and it did
great. On average, people lost 15 to 20%
of their body weight that were on it
over extended period of time, 6 months
to a year. And then a few years ago
tirzepatide came out, which is known by
the trade name Mounjaro. And that has
two agonists in it. So, it has the GLP-1
similar to semaglutide, but it also has
a GIP
agonist. And so, which is a insulin-type
agonist that helps with insulin
sensitivity as well.
And and those are the primary two that
are out on the market. There was a there
was one before Ozempic. I think it was
called
liraglutide, something like that.
And
and it wasn't as popular and it didn't
cause as much fat loss or or body weight
loss. It was under 10%. It was like 7 to
10%. But they continue to get better.
If you are on X or Twitter,
you've probably heard of retatrutide,
typically called reta.
It has three agonists. It has the GLP-1,
the GIP, and also a glucagon, excuse me,
glucagon agonist.
Which that glucagon piece is really like
the thing that makes everything. It just
It's just synergistic, all three of
these things. Glucagon causes increased
energy expenditure. Basically, your
basal metabolic rate goes up.
Um and you just burn more calories. It
helps your liver to dump
fat and get rid of fat in the liver
tremendously helping
the health of the liver. Visceral fat
has been fantastic with really all three
GLP's but certainly the retatrutide. And
so they're they're fantastic. However,
they come with some drawbacks. So one is
that some people have gastric distress
for some.
And I have not had any of that. I've
titrated up from very low dose to kind
of the standard dose and but some people
have some problems some nausea, some
some diarrhea or or even vomiting.
Again, that doesn't sound very
appetizing and but I haven't had any of
that but I certainly know of people who
have. I want to be careful with my my
words here but this is this is just what
it's called in the medical community.
It's almost forced anorexia. So for
those of you who are
overweight, your BMI is you know, way
over 30, 40, somewhere in that ballpark.
This is excellent. But for people who
are already struggling to maintain a
healthy body weight, this is probably
not a wise choice. There are people who
are taking it from the longevity
measures. They've really got to make
sure that they keep their protein and
their calories up which is very
difficult to do. You typically have to
drink a lot of calories, a lot of
protein shakes because you just don't
have the appetite to eat much food. And
so that can be a drawback for some.
And then the biggest one I think for our
community is that if they they're not
muscle sparing. At least the two that
are on the market now and I'll talk
about retatrutide
minute. Semaglutide and tirzepatide
what we've seen especially with
semaglutide is that when people lost
weight, they lost almost equal amounts
of fat and muscle. Almost exactly. And
tirzepatide was a little better
and and we don't have published studies
on retatrutide yet because it's in its
final stages of FDA approval
and and the studies. And so we just have
to go by experience what we hear other
people are on and kind of gather that
information.
But it seems like red light therapy does
a significantly better job at burning
fat and preserving muscle
as well as it doesn't seem to have the
the anorexic effect
or the lack of appetite that's quite as
intense as the other two. And so again,
that could be you could still overeat on
this but you just kind of don't want to.